10 Feb 2026 UPCOMING [Mar 11]: TI Best Evidence Webinar: The good, the bad and the ugly – rational PPI choices
In this TI Best Evidence Webinar, Dr. Aaron M Tejani will present evidence supporting rational choice of proton pump inhibitors (PPI) by reviewing head-to-head RCTs and critically examining manufacturer claims. The presentation will revisit the topic of the Therapeutics Letter #126: Serious harms with long-term PPI use in older adults published in June 2020 and the associated personal prescribing Portrait sent to approximately 5,400 family doctors in BC between March and June 2020. Dr. Tejani will also include evidence comparing the use of PPI racemic mixtures vs enantiomers, such as omeprazole vs esomeprazole, lansoprazole vs dexlansoprazole, from the upcoming Therapeutics Letter 160.
TITLE: The good, the bad and the ugly – rational PPI choices
WHEN: 12:00 – 1:00 PM PDT on Wednesday, March 11, 2026 [convert to your local time]
WHERE: This is a free virtual event. Anyone can attend but registration is required. After submitting your registration you will receive a confirmation email, which will include connection details.
SPEAKER: Dr. Aaron M Tejani BSc (Pharm), PharmD, Chair of the Education Working Group, UBC Therapeutics Initiative.
REGISTRATION: https://ubc.zoom.us/meeting/register/9QZ_kgGERN6tBpkfaAkCAg
CME CREDITS: The Division of Continuing Professional Development, University of British Columbia Faculty of Medicine (UBC CPD) is fully accredited by the Continuing Medical Education Accreditation Committee (CACME) to provide CPD credits for physicians. This activity meets the certification criteria of the College of Family Physicians of Canada and has been certified by UBC CPD for up to 2.0 Mainpro+ Certified Activity credit, consisting of 1.0 Base Activity credit available to everyone who attends plus an additional 1.0 Enhanced Activity credit available to BC family physicians and nurse practitioners signed up for the Portrait program. Each physician should claim only those credits accrued through participation in the activity to which they are entitled.
LEARNING OBJECTIVES (by the end of this session, participants will be able to):
- Consider use of prescription H2RA’s, such as cimetidine, or over-the-counter antacids for new presentations of GERD/heartburn, and include patient instructions to review dietary triggers.
- Limit duration of new PPI prescriptions to maximum 4 weeks, documenting indication and expected length of treatment for new prescriptions and adding this info to each prescription to ensure that the community pharmacy colleague is aware.
- Make rational choices among available PPIs, including between racemic mixtures and enantiomers.
- Use their personal prescribing Portrait on this topic to optimize their prescribing by reflecting on how their prescribing of these medications compares with their peers in BC and with the latest evidence-based recommendations.
About the topic: The proton pump inhibitors (PPIs) were introduced in 1988. Health Canada, professional, and academic groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand at alarming rates. Starting in 2009, Health Canada and other regulators have reported a number of drug interactions and adverse events associated with PPIs. Many professional associations and independent drug bulletins recommend reducing PPI exposure and provide tools for deprescribing. Encouraging restraint has yet to achieve a measurable impact on long-term PPI prescribing for the common indications. Is the evidence of harms sufficient that we should intensify efforts to constrain new prescriptions and to deprescribe for long-term users? To make matters worse, manufacturers’ ever greening strategies resulted in the introduction of enantiomers with no superior efficacy or safety but significantly increased cost. In the TI Best Evidence Webinar, Dr. Aaron M Tejani will review the best available evidence at this time and provide practical tips for prescribers on how to make rational PPI choices He will also demonstrate how BC family physicians and nurse practitioners can optimize their prescribing of PPIs by using their personal prescribing Portrait on this topic to reflect on how their prescribing of these medications compares with their peers in BC and with the latest evidence-based recommendations. This TI Best Evidence Webinar revisits the topic of the Therapeutics Letter #126: Serious harms with long-term PPI use in older adults published in June 2020 and the associated personal prescribing Portrait sent to approximately 5,400 family doctors in BC between March and June 2020. Dr. Tejani will also include evidence comparing the use of PPI racemic mixtures vs enantiomers, such as omeprazole vs esomeprazole, lansoprazole vs dexlansoprazole, from the upcoming Therapeutics Letter 160.
About the speaker: Dr. Aaron M Tejani BSc (Pharm), PharmD is a researcher/educator with the Therapeutics Initiative (Chair of the Education Working Group, member of the Drug Assessment Working Group), clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of Pharmacy degree at Creighton University (Omaha, Nebraska).
No Comments